Richard Lowenthal

We would probably be adding on other allergy assets to help build the company.

But again, initially, I would say for the next 9 to 12 months, we want to focus on NEFI and making sure that we start to build that brand as well as we can.

And then start looking at other allergy assets that would make sense for our sales force.

which is mainly focused on allergists and pediatricians and move down that pathway.

And I think for that, we'd also be agnostic to the route of administration.

So if we find a good allergy asset that makes sense for ARS, I don't think we would be, you know, specific to intranasal products versus other routes of administration.

We'd be pretty agnostic to that.